Table 2.

Regression results testing the consistency between atlas-based plans and custom-based plans for various dose metrics

	Slope estimate	95% confidence interval
PBM
V10, %	1.004	[0.995-1.012]
V20, %	1.021	[1.005-1.037]
Dmean, Gy	1.014	[1.006-1.022]
ABMcustom
V10, %	0.982	[0.972-0.993]
V20, %	0.997	[0.976-1.020]
Dmean, Gy	1.006	[0.991-1.020]
Bowel
D30, Gy	1.003	[0.992-1.013]
Dmax, Gy	0.998	[0.995-1.001]
V45, cc	0.998	[0.985-1.011]
Rectum
D50, Gy	0.999	[0.997-1.002]
D60, Gy	0.999	[0.996-1.003]
Dmax, Gy	0.996	[0.992-1.000]
Bladder
D50, Gy	0.998	[0.996-1.000]
Dmax, Gy	0.999	[0.994-1.003]
Femoral heads
D15, Gy	0.986	[0.946-1.025]
Dmax, Gy	0.84 (0.07) 0.994	[0.980-1.019]
PTV45 (n = 23)
D95, Gy	1.000	[0.999-1.000]
D97, Gy	1.000	[0.999-1.001]
D99, Gy	1.001	[0.999-1.003]
D95, Gy	1.002	[0.999-1.004]
PTV47.6 (n = 9)
(n = 9)
D97, Gy	1.003	[0.999-1.006]
D99, Gy	1.006	[0.999-1.013]
PTVBoost (n = 9)
D95, Gy	0.999	[0.997-1.001]
D97, Gy	0.999	[0.997-1.001]
D99, Gy	0.999	[0.996-1.001]

Abbreviations: ABM = active bone marrow; PBM = pelvic bone marrow; PTV = planning target volume.

Each row lists the estimates and 95% confidence intervals for the best-fit slope. A slope greater than unity indicates a higher dose-volume metric for the custom-based plan relative to the atlas-based plan.